Navigation Links
A way to slow the progression of Type 1 Diabetes

According to new research, a new drug that suppresses the immune system may slow the progression of type 1 diabetes. An early-phase clinical trial of 10 people aged 8 to 35 years with type 1 diabetes were treated with anti-CD3 mAb, a modified antibody.// A 14-day course of the drug appeared to slow the progressive decline in insulin production commonly seen in type 1 diabetics.

Patients with type 1 diabetes eventually lose the ability to produce insulin entirely and rely solely on injected insulin to maintain control of their good sugar levels. However, the 12 patients treated with anti-CD3 mAb produced more natural insulin and needed less injected insulin one year after treatment they untreated patients. Researchers believe the drug works on the immune system's destructive T-cells, and effectively suppresses the immune cells involved in the development of diabetes. They believe it also helps to retain insulin production well into the course of the disease.

Kevan Herott, M.D., of Columbia University, felt that, the goal of this trial was to induce tolerance to the beta cell, which is the target of autoimmune destruction in type 1 diabetes. This was in effect achieved, because the clinical effect we saw persisted long after patients had finished treatment with the anti-CD3 antibody.


'"/>




Page: 1

Related medicine news :

1. Hip X-ray can help to find out progression of osteoarthritis
2. Malaria infection can accelerate HIV infection and disease progression
3. Is Diabetes the Leading Cause of Kidney Failure in India
4. Diabetes and Depression often go hand-in-hand
5. Thirty minutes of work up per day reduces the risk of Diabetes
6. Diabetes on the rise
7. Irregular Periods Linked to Diabetes
8. Cinnamon combats Diabetes
9. Good News For Women With Gestational Diabetes
10. Processed Meat, Diabetes connection Found
11. Pancreatic Cancer may be linked to Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... , ... Goodcents Deli Fresh Subs today announced the opening of a new ... St. Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by ... locations in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... ... , ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an ... 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ... Denmark in 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in ...
(Date:6/23/2017)... TX (PRWEB) , ... June 23, 2017 , ... All-Star ... to residential and business clients throughout eastern Texas, is announcing the launch of a ... , Recent breast cancer statistics in the United States reveal that an estimated 252, ...
(Date:6/22/2017)... ... 22, 2017 , ... Plastic Surgery Associates is proud to report that founding ... year, research and information firm, Castle Connolly, releases their list of the most notable ... the 3rd time that Dr. Canales has been recognized by Castle Connolly. ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: